Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Sorrento Therapeutics, Inc. | Financial_Report.xls |
| 10-K - FORM 10-K - Sorrento Therapeutics, Inc. | d444183d10k.htm |
| EX-32.1 - EX-32.1 - Sorrento Therapeutics, Inc. | d444183dex321.htm |
| EX-31.2 - EX-31.2 - Sorrento Therapeutics, Inc. | d444183dex312.htm |
| EX-31.1 - EX-31.1 - Sorrento Therapeutics, Inc. | d444183dex311.htm |
| EX-10.30 - EX-10.30 - Sorrento Therapeutics, Inc. | d444183dex1030.htm |
| EX-10.28 - EX-10.28 - Sorrento Therapeutics, Inc. | d444183dex1028.htm |
| EX-10.29 - EX-10.29 - Sorrento Therapeutics, Inc. | d444183dex1029.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement No. 333-163670 on Form S-8 of our report dated March 25, 2013, which includes an explanatory paragraph related to the uncertainty of the Company’s ability to continue as a going concern, relating to the consolidated financial statements of Sorrento Therapeutics, Inc. and Subsidiary for the year ended December 31, 2012, appearing in this Annual Report on Form 10-K of Sorrento Therapeutics, Inc. and Subsidiary.
/s/ Mayer Hoffman McCann P.C.
San Diego, California
March 25, 2013